Stryker Corporation (SYK)

In the past six months, Stryker's stock price has seen an increase. As of June 20, 2025, the share price was $375.56, representing a 10.76% increase from June 24, 2024. The stock was up 1.73% over the past 30 days and 14.65% over the past 12 months as of June 27, 2025. Stryker announced better-than-expected revenue in Q1 CY2025, with sales up 11.9% year-on-year to $5.87 billion, exceeding analyst estimates. On May 8, 2025, Stryker declared an $0.84 per share quarterly dividend. Stryker recently acquired Inari Medical for $4.9 billion, marking its entry into the mechanical thrombectomy market, and divested its spinal implant business as part of a repositioning strategy. The company increased its revenue and earnings guidance for fiscal year 2024.

The medical devices industry generally experiences steady demand. While specific seasonal fluctuations for Stryker's products are not explicitly detailed, the company's diverse product portfolio positions it to capture growth in both elective procedures and emergency medical care. The demand for advanced medical devices and technologies is poised to rise as healthcare systems globally continue to evolve. The shift towards ambulatory surgical centers is also a favorable trend for Stryker.

Stryker Corporation is a global leader in medical technology, specializing in the design, manufacture, and marketing of medical equipment and devices across the fields of medical surgery, neurotechnology, and orthopaedics. The company operates primarily within the Healthcare sector, specifically in the Medical Devices industry. Stryker's extensive product portfolio is categorized into two main segments: MedSurg and Neurotechnology, and Orthopaedics. MedSurg and Neurotechnology includes surgical equipment and navigation systems, endoscopic and communications systems, patient handling, emergency medical equipment, intensive care disposable products, clinical communication, workflow solutions, and products for the treatment of acute ischemic and hemorrhagic stroke, traditional brain, and open skull-based surgical procedures. Orthopaedics focuses on implants used in hip and knee joint replacements, trauma and extremity surgeries, and cervical, thoracolumbar, and interbody systems. Stryker offers its products to doctors, hospitals, and other healthcare facilities.

Stryker maintains a significant global presence, selling its products in approximately 75 countries through company-owned subsidiaries, branches, and third-party distributors. In 2024, approximately 27% of Stryker's net sales were generated outside the United States. The company's expansive reach provides a diversified revenue base, helping to mitigate risks associated with regional economic fluctuations. International sales, particularly in emerging markets, have contributed significantly to its growth.

Stryker has a strong reputation for quality and innovation among surgeons and hospitals. The company's dedication to innovation and quality has established its reputation as a pioneer in the medical field. Forbes lists Stryker among the "Most Trusted Companies in America" for 2025. The company may be adversely affected by product liability claims, unfavorable court decisions, legal settlements, or regulatory enforcement actions. Failure to satisfy evolving criteria or accurately disclose progress related to corporate ESG initiatives could lead to reduced demand, decreased profits, increased investigations, litigation, and reputational damage. Physical effects of climate change or measures to address it could cause significant business and supply chain interruptions, potentially impacting reputation.

Stryker Corporation is largely controlled by institutional shareholders, who own approximately 77.55% to 79% of the company. A total of 3,247 to 3,271 institutional owners and shareholders hold a significant portion of the shares, ranging from 341,013,179 to 341,706,075 shares. Major institutional owners include Vanguard Group Inc., BlackRock, Inc., Greenleaf Trust, State Street Corp, JPMorgan Chase & Co, Price T Rowe Associates Inc /md/, Fmr Llc and Geode Capital Management, Llc. Individual ownership accounts for about 6.29% of the company. Notable individual shareholders (insiders) include members of the Stryker family: Jon L. Stryker, Ronda E. Stryker, Pat Stryker and John W. Brown.